K. Desai

Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability

R. Bentley, K. Leander, L. Sepp-Lorenzino, 2015, Thrombosis and Haemostasis.

Development of a novel tricyclic class of potent and selective FIXa inhibitors.

J. Metzger, R. Berger, Hong Li, 2015, Bioorganic & medicinal chemistry letters.

A rabbit model of cerebral microembolic signals for translational research: preclinical validation for aspirin and clopidogrel

D. Seiffert, D. Gutstein, Xinkang Wang, 2016, Journal of thrombosis and haemostasis : JTH.

MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.

D. K. Wood, E. Schonbrun, F. Musayev, 2019, Blood advances.

PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.

A. Peier, A. Pocai, R. Laufer, 2012, Bioorganic & medicinal chemistry.

Development of a neuromedin U–human serum albumin conjugate as a long‐acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide

A. Peier, A. Pocai, R. Laufer, 2014, Journal of peptide science : an official publication of the European Peptide Society.

The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).

A. Peier, N. Hastings, D. Marsh, 2009, Endocrinology.

Effects of peripherally administered neuromedin U on energy and glucose homeostasis.

A. Peier, J. Metzger, Liming Yang, 2011, Endocrinology.

Development of a novel class of potent and selective FIXa inhibitors.

E. Sherer, K. Ellsworth, W. Geissler, 2015, Bioorganic & medicinal chemistry letters.